 |
|
Increased Expression of the Epidermal Growth Factor Receptor on Human Colon Carcinoma Cells
Stephen J. Bradley, MD;
Geri Garfinkle;
Elizabeth Walker;
Ronald Salem, FRCS;
Lan Bo Chen, PhD;
Glenn Steele, Jr, MD, PhD
Arch Surg. 1986;121(11):1242-1247.
Abstract
• Epidermal growth factor (EGF) is a small polypeptide hormone that promotes the growth of cells in culture and elicits the differentiation of epithelial tissues in vivo. The effect of EGF is mediated by a transmembrane receptor that is expressed in increased amounts on some tumor cells. We have used a monoclonal antibody to the EGF receptor to detect increased expression of the receptor on human colon carcinoma cells. All eight of the moderately well-differentiated colon carcinoma cell lines tested and several frozen colon carcinoma tissue sections showed increased expression of the EGF receptor, while five poorly differentiated colon carcinoma cell lines and normal colon tissue sections did not. Increased expression of the EGF receptor on moderately welldifferentiated colon carcinoma cells but not on poorly differentiated colon carcinoma cells was also demonstrated by western transfer and iodine 125–labeled EGF binding assays. Increased expression of the EGF receptor on moderately welldifferentiated colon carcinoma cells seems to be a useful marker for the differentiation of human colon carcinoma cells. In addition, it might provide a site for adjuvant hormonal therapy or immunotherapy.
(Arch Surg 1986;121:1242-1247)
Author Affiliations
From the Department of Surgery, New England Deaconess Hospital (Drs Bradley, Salem, and Steele), and the Dana Farber Cancer Institute (Drs Chen and Steele and Mss Garfinkle and Walker), Boston.
Footnotes
Accepted for publication July 31, 1981.
Read before the 39th Annual Meeting of the Society of Surgical Oncology, Washington, DC, May 12, 1986.
Reprint requests to Department of Surgery, New England Deaconess Hospital, 110 Francis St, Boston, MA 02115 (Dr Steele).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group
Canil et al.
JCO 2005;23:455-460.
ABSTRACT
| FULL TEXT
|
